drugset / Trial / NCT00299611
Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the effectiveness of Levetiracetam augmentation relative to Placebo in SSRI non-remitters with obsessive compulsive disorder. The hypothesis is that anxiolytic effect of Levetiracetam is more beneficial when adding with a SSRI.
Timeline
- Start
- 2005-11
- Primary completion
- 2007-12
- Completion
- 2008-04
Publications
- Background Ellingrod VL. Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature. Pharmacotherapy. 1998 Sep-Oct;18(5):936-60.
- Background Sasson Y, Zohar J, Chopra M, Lustig M, Iancu I, Hendler T. Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry. 1997;58 Suppl 12:7-10.
- Background Steketee G. Disability and family burden in obsessive-compulsive disorder. Can J Psychiatry. 1997 Nov;42(9):919-28. doi: 10.1177/070674379704200902.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Levetiracetam | Other / unclassified | 500 mg | — |
| Comparator | Sertraline | Small molecule | 50 mg | — |